Dialyzing women and men: does it matter?
An observational study

Ayse Serra Artan1, Fatih Kircelli2, Ercan Ok3, Murvet Yilmaz4, Gulay Asci3, Cengiz Dogan5, Ozgur Oto1, Kutay Gunestepe2, Ali Basci3 and Mehmet Sukru Sever1

1Division of Nephrology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul, Turkey, 2Fresenius Medical Care, Istanbul, Turkey, 3Ege Medical Faculty, Izmir, Turkey, 4Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey and 5CEND Consulting, Istanbul, Turkey

Correspondence and offprint requests to: Ayse Serra Artan; E-mail: ayseserra@gmail.com

Abstract

Background: Application and consequences of hemodialysis treatment may differ between genders; focusing on these differences may be useful to optimize outcomes.

Methods: Data from 1 999 648 hemodialysis sessions performed in 10 984 (3316 incident and 7668 prevalent) patients, treated in 55 centers of the European Clinical Database (EuCliD)–Turkey, were analyzed, and various demographic, clinical, biochemical, therapeutic and prognostic parameters were compared.

Results: There were 1905 male and 1411 female incident and 4339 male and 3329 female prevalent patients. For females, the mean age in incident (61.8 ± 14.9 years) and prevalent (58.3 ± 15.2 years) patients was higher than for males (60.2 ± 14.8 and 56.5 ± 14.9 years, respectively) (P < 0.001 for both analyses). Also, body mass index was higher, while the hemoglobin level, and the percentage of interdialytic weight gain and arteriovenous fistula were lower. Serum phosphorus was similar in both genders in incident cases, while it was lower in prevalent female patients. Serum parathyroid hormone levels were lower in incident, but higher in prevalent male cases. Erythropoiesis-stimulating agents and vitamin D preparations were more frequently used in female incident and prevalent patients. Hospitalization was more frequent in prevalent females, while it did not differ significantly in the incident cases. Overall, no significant difference was observed in survival rates at 3 years in both incident and prevalent male and female patients.

Conclusions: Many parameters differ significantly between female and male dialysis patients. Considering the effects of sex on several parameters may be a valuable approach for achieving better outcomes when formulating treatment strategies in this patient population.

Key words: end-stage renal disease, gender, hemodialysis treatment

Received: November 12, 2015. Accepted: February 9, 2016
© The Author 2016. Published by Oxford University Press on behalf of ERA-EDTA.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Introduction

The mortality risk in chronic hemodialysis patients is unacceptably high, with a 5-year survival rate of only 36% in incident cases [1]. Since many traits and also comorbidities differ significantly among the patients, individualization of therapy may be useful for improving outcomes. Accordingly, a tailor-made treatment protocol needs to consider gender-related differences, because not only demographic characteristics but also many clinical, laboratory and therapeutic features that may affect morbidity and mortality differ significantly between the two genders.

However, apart from a very recent Dialysis Outcomes and Practice Patterns Study (DOPPS) study [2], no study had been specifically designed to search for sex-related differences in hemodialysis practice; the effects of gender on the dose of hemodialysis, erythropoietin requirements, vascular access and compliance have been reported only in the context of subgroup analyses [3–6]. We therefore analyzed a large cohort of hemodialysis patients in order to investigate the effects of several variations on the outcomes in male and female cases.

Materials and methods

Study population

The European Clinical Database (EuCliD®) collects clinical, laboratory and prognostic parameters of hemodialysis patients who are being dialyzed in various centers of Fresenius Medical Care (FMC) localized in different countries since 2002 [7]. We obtained data on 1 999 648 hemodialysis sessions performed in 10 984 (3316 incident and 7668 prevalent) patients, dialyzed in 55 centers of FMC–Turkey. Patients with acute kidney injury were not included in the study.

Incident patients were defined as those who had started maintenance hemodialysis treatment within the preceding 3 months in an FMC clinic, or in other dialysis centers, but moved to an FMC chain within the study period (between May 2009 and May 2012). Prevalent patients were defined as those receiving chronic hemodialysis for >3 months.

Participants were followed up until death or up to leaving of the FMC clinics for any reason. Thus, follow-up time was censored at the study end for patients who did not leave the facility. With regard to the mortality statistics, the data on patients who died within the first month after leaving the FMC chain were analyzed as well. By using this methodology, the time period when the patients were under observation and 1 month after leaving the FMC chain was included in the survival analyses.

Demographic data were retrieved from the patient files. Information regarding hemodialysis application was entered into the EuCliD database instantly via electronic data input devices (personal digital assistant) and desktop computers by the attending nurses during each hemodialysis session. Laboratory data were imported to EuCliD directly from database of the laboratory service provider via an interface.

Data for the patients who had left FMC clinics were obtained by repeated, various types of communications between the FMC clinics’ and new clinics’ head nurses.

Measurements

Blood pressure was measured a minimum of five times (before, at hourly intervals and after) in each dialysis session. More frequent measurements were performed in the case of any subjective complaints, symptoms or complications. Monthly blood urea nitrogen, creatinine and potassium levels were measured in both predialysis and postdialysis serum samples. Serum glucose, sodium, calcium, phosphorus, total protein, albumin, alanine aminotransferase levels and hemogram were determined monthly in the predialysis serum specimens. Serum iron, iron binding capacity, ferritin, parathyroid hormone (PTH) and HbA1c levels were measured at 3-monthly intervals. All of the laboratory parameters were determined in four central laboratories, which were registered to several quality-control program audits and are certificated by international agencies at least twice per year.

Outcomes

The odds of achieving many clinical, therapeutic and laboratory targets, hospitalization and the probability of patient survival by gender were evaluated as outcome measures.

Statistical analysis

Descriptive statistics for all numeric variables, including means, standard deviations together with the proportions of all categorical variables, were calculated. Mann–Whitney U-test was used when the numeric variables did not distribute normally in the independent two groups. Differences between group proportions were examined by $\chi^2$ analysis.

The probability of patient survival according to gender was estimated using a generalization of the Kaplan–Meier estimates. The survival of the patients who had achieved ideal (reference) targets was then compared with the patients who were characterized by lower or higher values than the reference with Kaplan–Meier log rank test.

The association between gender and mortality was assessed using Cox regression models adjusted for age, body mass index (BMI), and time period with end-stage renal disease and many comorbid conditions [including vascular access, percentage of dialysis sessions performed by using arteriovenous fistula (AVF), arteriovenous graft (AVG), permanent or temporary catheters], dialysis prescriptions [mean treatment time, blood flow, ultrafiltration rate, single pool Kt/V], hemoglobin, serum albumin, calcium, phosphorus and PTH].

SPSS 15.0 for Windows was used to conduct the statistical analysis.

Statistical significance was accepted at P-values <0.05.

This study was approved by the Istanbul School of Medicine Clinical Studies Board/Ethics committee (Approval No.: 2014/ 1391). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.

Results

Incident patients

Demographic features

Overall, there were 3316 incident patients; of these, 1905 were males and 1411 females. The total number of hemodialysis sessions in the incident patients was 399 954. Females underwent 176 142 sessions; this figure was 223 812 for the males.

Males were significantly younger compared with the females, while females had higher BMI values (Table 1). When compared
with the reference values, higher than ideal BMI was associated with better survival in both genders, while lower BMI was associated with a worse survival only in the males (Table 2).

Table 1. Demographic characteristics, features of hemodialysis practice and laboratory parameters in incident and prevalent male and female patients

| Parameter                          | Incident patients | Prevalent patients |
|------------------------------------|-------------------|--------------------|
|                                   | Female            | Male               | P      | Female            | Male               | P      |
| Age (years)                        | 61.8 ± 14.9       | 60.2 ± 14.8        | 0.001  | 58.3 ± 15.2       | 56.5 ± 14.9        | <0.001 |
| BMI (kg/m²)                        | 26.8 ± 6.2        | 24.7 ± 4.5         | <0.001 | 25.8 ± 5.6        | 24.6 ± 4.4         | <0.001 |
| Dialysis vintage (months)          | 0.5 ± 0.9         | 0.6 ± 0.9          | 0.6    | 62.7 ± 54.6       | 61.6 ± 54.0        | 0.3    |
| DM (%)                             | 39.8              | 34.6               | 0.003  | 28.5              | 27.2               | 0.2    |
| AVF (%)b                           | 48.8 ± 44.3       | 57.5 ± 43.3        | <0.001 | 77.2 ± 37.9       | 85.4 ± 31.1        | <0.001 |
| AVG (%b)                           | 1.7 ± 12.0        | 1.3 ± 10.1         | 0.08   | 3.9 ± 17.9        | 2.0 ± 13.1         | <0.001 |
| Untunneled catheter (%b)           | 19.3 ± 34.7       | 19.1 ± 34.4        | 0.9    | 2.0 ± 11.4        | 1.5 ± 10.4         | 0.001  |
| Tunneled catheter (%b)             | 27.7 ± 41.2       | 19.2 ± 35.8        | <0.001 | 12.1 ± 29.9       | 6.4 ± 22.3         | <0.001 |
| Blood flow (mL/min)                | 296.3 ± 45.8      | 306.4 ± 45.6       | <0.001 | 319.5 ± 43.3      | 332.0 ± 41.2       | <0.001 |
| Kt/V                               | 1.4 ± 0.3         | 1.2 ± 0.2          | <0.001 | 1.6 ± 0.3         | 1.4 ± 0.2          | <0.001 |
| Creatinine (mg/dL)                 | 5.83 ± 1.86       | 6.75 ± 2.31        | <0.001 | 7.13 ± 1.68       | 8.51 ± 2.25        | <0.001 |
| Potassium (mmol/L)                 | 4.77 ± 0.74       | 4.75 ± 0.72        | 0.1    | 5.06 ± 0.62       | 5.08 ± 0.62        | 0.4    |
| Albumin (g/dL)                     | 3.68 ± 0.47       | 3.72 ± 0.49        | 0.01   | 3.91 ± 0.32       | 3.98 ± 0.34        | <0.001 |
| Calcium (mg/dL)                    | 8.65 ± 0.70       | 8.61 ± 0.61        | 0.02   | 8.95 ± 0.65       | 8.93 ± 0.64        | 0.1    |
| Phosphorus (mg/dL)/n               | 4.56 ± 1.20       | 4.61 ± 1.21        | 0.5    | 4.74 ± 1.10       | 4.91 ± 1.20        | <0.001 |
| PTH (pg/mL)                        | 304.3 ± 247.9     | 281.5 ± 219.8      | 0.03   | 401.5 ± 370.3     | 429.5 ± 388.8      | 0.02   |
| Hemoglobin (g/dL)                  | 10.35 ± 1.26      | 10.71 ± 1.32       | <0.001 | 11.19 ± 1.13      | 11.68 ± 1.26       | <0.001 |
| Ferritin (ng/mL)                   | 688.3 ± 520.2     | 597.4 ± 440.2      | <0.001 | 905.8 ± 549.1     | 728.14 ± 527.1     | <0.001 |

BMI, body mass index; DM, diabetes mellitus; AVF, arteriovenous fistula; AVG, arteriovenous graft; PTH, parathyroid hormone.

a All laboratory parameters were assessed in predialysis serum samples.

b Percentage of dialysis sessions performed by this particular access.

Table 2. Three-year survival rates with regard to several parameters in the incident male and female patients

| Parameter                           | P<Reference | Reference | >Reference | P** |
|-------------------------------------|-------------|-----------|------------|-----|
| BMI                                 | 0.087       | <21 kg/m² (n) | 21–25 kg/m² (n) | 25 kg/m² (n) | 0.009 |
| Male                                | 0.001       | 53.1% (324) | 66.1% (689) | 73.5% (726) | 0.002 |
| IDWG/dry weight                     | <0.001      | 46.8% (188) | 75.8% (1012) | 65.3% (144) | 0.168 |
| Female                              | <0.001      | 38.9% (259) | 69.6% (1332) | 67.8% (213) | 0.646 |
| Male                                | <0.001      | 29.5% (39)  | 72.2% (761) | ***(1) | *** |
| Predialysis systolic BP             | <0.001      | 22.0% (35)  | 71.5% (1032) | ***(0) | *** |
| Female                              | <0.001      | <12 (120) | 1.2–1.4 | >1.4 |
| Male                                | <0.001      | 39.2% (166) | 70.9% (409) | 76.1% (672) | 0.028 |
| Hb                                  | <0.001      | <9 g/dL | 11–12 g/dL | >13 g/dL | *** |
| Female                              | <0.001      | 29.8% (191) | 78.9% (602) | 57.3% (55) | 0.109 |
| Male                                | <0.001      | 44.1% (196) | 75.8% (865) | 65.5% (209) | 0.188 |
| Phosphorus                          | <0.001      | <3.5 mg/dL | 3.5–5.5 mg/dL | 5.5 mg/dL | 0.009 |
| Female                              | <0.001      | 48.5% (247) | 64.6% (1134) | 83.3% (337) | 0.092 |
| Male                                | <0.001      | <130 pg/mL | 130–585 pg/mL | >585 pg/mL | 0.024 |
| PTH                                 | <0.001      | 59.3% (247) | 77.3% (798) | 47.6% (110) | 0.943 |
| Female                              | <0.001      | 59.8% (363) | 69.3% (1070) | 68.1% (106) | 0.027 |
| Male                                | <0.001      | 16.9% (294) | 75.4% (722) | 83.3% (253) | 0.001 |
| Overall dialysis vintage did not show a difference between males and females. Frequency of diabetic nephropathy was significantly higher among females. The number of patients being

BMI, body mass index; BP, blood pressure; Hb, hemoglobin; PTH, parathyroid hormone, IDWG, interdialytic weight gain.
P*: statistics for comparing lower values than the reference.
P**: statistics for comparing higher values than the reference.
***: statistics unavailable because of insufficient number of patients or a follow-up <3 years.
transferred to peritoneal dialysis (PD) was very low; in the incident patients, three females and two males were switched to PD. More [63 (3.3%)] males were transplanted compared with females [23 (1.6%)] (P = 0.003).

**Dialysis practice**

AVF was the most frequently used vascular access type in both genders; it was even more frequently used in males when compared with females, while tunneled catheter usage was more frequent in females (Table 1).

AVF usage was associated with better survival in both genders when compared with central catheters; however, when compared with AVG as a vascular access, usage of AVF was characterized by better survival in males, but not in females (data not shown).

Interdialytic weight gain (IDWG)/dry weight was 2.7 ± 1.4 and 2.8 ± 1.4% in the females and males, respectively (P = 0.020). An IDWG/dry weight <1.4% was associated with worse survival in both genders; patients with IDWG/dry weight >4.2% were characterized by an unfavorable outcome as well, however, without significance (Table 2). Predialysis systolic (130.6 ± 15.7 versus 126.7 ± 15.4 mmHg) and diastolic (77.6 ± 8.0 versus 76.4 ± 8.1 mmHg) blood pressures were higher (P < 0.001 for both analyses) in males when compared with the females. Lower blood pressures were associated with significantly worse survival in both sexes (Table 2).

**Laboratory parameters, and erythropoiesis-stimulating agents and vitamin D usage**

Laboratory variables in both sexes are shown in Table 1. In the univariate outcome analysis, which compares higher and lower values with the targets, the following findings were noted: males with lower or higher hemoglobin values were characterized by worse survival, although the latter did not reach significance (Table 2). Low phosphorus values were associated with unfavorable survival in both sexes; males, but not females, were characterized by better survival with higher serum phosphorus. Lower and higher PTH values indicated a poor survival in both genders; however, this did not reach significance in male patients with high PTH values. Considering serum albumin, lower values were associated with poor survival in both genders (Table 2).

The percentage of patients who had been prescribed erythropoiesis-stimulating agents (ESAs) was higher in female patients (75.5%) when compared with male patients (73.9%), however without statistical significance (P = 0.305). Of note, despite vitamin D preparations having been prescribed more frequently (43.8 versus 38.2%) (P < 0.001), serum PTH levels were higher in the females. Glycemic control, determined by HbA1c levels, was similar in male (7.7 ± 1.7%) and female (7.7 ± 1.8) cases (P = 0.6).

**Hospitalization and survival**

Frequency of hospitalization was 33.0% in female patients, while this figure was 32.4% for the male patients (P = 0.7). 295 males and 199 females died among the incident patients, giving rise to mortality rates of 14.1% in female patients and 15.5% in male patients (P = 0.3). Survival rates within the first 3 months did not differ significantly between the two genders (data not provided). One-, two- and three-year survival rates were 84.9, 77.3 and 71.5%, respectively, in the female patients; corresponding figures were 83.1, 76.2 and 65.9% in the males, respectively (P = 0.2) (Figure 1).

The comparison of the survival rates of the male and female incident patients who achieved or did not achieve ideal targets (reference values) for several demographic, clinical, biochemical and therapeutic parameters is shown in Table 2.

In the multivariate analysis, age, tunneled and untunneled catheter usage, BMI, Kt/V, blood pump rate, hemoglobin, serum albumin and calcium values were found to be predictors for mortality (Table 3).

**Prevalent patients**

**Demographic features**

In total, there were 7668 prevalent patients; of these, 4339 and 3329 were males and females, respectively. The number of hemodialysis sessions performed in these patients was 1 599 694. Males were treated by 880 615 sessions; this figure was 719 079 for the female patients. Similar to the incident cases, female patients were characterized by older age and higher BMI (Table 1). When compared with the reference values, significantly better
and worse survival rates were noted with higher and lower BMI scores, respectively, in both genders; however, the latter did not reach statistical significance in the females.

Forty percent of the female patients had been on hemodialysis treatment for <1 year; 30% had been receiving dialysis for >36 months. Corresponding figures for the male patients were 43.1 and 27.8%, respectively. Overall dialysis vintage did not reach statistical significance between the genders. There was only one female patient moving to PD modality from hemodialysis, whereas 144 (3.3%) males and 96 (2.9%) females were transplanted (P = 0.278).

### Discussion

Dialysis practice

AVF was used more frequently in males, whereas tunneled and untunneled catheters, and also AVG were used more frequently in females (Table 1). Usage of AVF was associated with more favorable outcome in both genders when compared with central catheters; however, statistical analysis revealed no survival difference in patients who had used AVF or AVG for vascular access (data not shown).

Similar to the incident cases, Kt/V was significantly higher in females. In both genders, survival rate decreased with lower (<1.2) Kt/V; higher (>1.4) Kt/V was associated with better outcome only in the females.

IDWG/dry weight was 3.3 ± 1.4% in the females and 3.4 ± 1.3% in males, respectively (P < 0.001). An IDWG/dry weight <1.7% was associated with worse survival in both genders; a more favorable outcome was noted in the patients with higher than reference values, however without significance (Table 4).

Predialysis systolic (124.2 ± 17.5 versus 131.2 ± 17.3 mmHg) and diastolic (73.5 ± 9.0 versus 76.6 ± 8.5 mmHg) blood pressures were lower in the females when compared with males (P < 0.001 for both analyses). Male patients with systolic blood pressures <100 mmHg were characterized by a significantly worse survival, whereas this was not the case for females.

### Laboratory parameters, and ESA and vitamin D usage

Laboratory parameters are shown in Table 1. Univariate outcome statistics revealed the following findings: both genders were characterized by worse survival in patients with hemoglobin values below 9 g/dL. Hemoglobin values >13 g/dL were associated with worse survival in females, but better survival in males, when compared with the cases with hemoglobin between 11 and 12 g/dL. Lower serum phosphorus (<3.5 mg/dL) was associated with worse survival in both genders; males, but not females, were characterized by a better survival with higher serum phosphorus (>5.5 mg/dL). Lower PTH values (<130 pg/mL) were associated with worse survival in both genders. Male patients with higher (>585 pg/mL) PTH values were noted to have better survival. Serum albumin <3.5 g/dL was associated with poor survival in both genders (Table 4).

ESAs were more frequently used in female patients (75.2%) compared with male patients (65.0%) (P < 0.001). The percentage of patients on vitamin D preparations was higher (56.2%) in females as well, when compared with males (51.6%) (P < 0.001).

### Hospitalization and survival

Frequency of hospitalization was more frequent in females when compared with males (31.4 versus 27.7%) (P = 0.001). Overall, 575 males and 463 females among the prevalent patients died, giving rise to mortality rates of 13.9% in females and 13.3% in males (P = 0.4). Survival rates within the first 3 months did not differ significantly between the two genders (data not provided).

One-, two- and three-year survival rates (92.2, 84.0 and 76.4%, respectively) for female patients did not differ significantly when compared with the corresponding figures in the males (92.2, 84.0 and 76.7%, respectively) (P = 0.888) (Figure 1). The survival rates, with regard to achievement of several ideal parameters, are shown in Table 4.

In the multivariate analysis, age, IDWG/dry weight, female gender, AVF, tunneled and untunneled catheter usage, BMI, Kt/V, processed blood volume, hemoglobin, serum albumin, phosphorus and calcium predicted mortality (Table 3).

### Table 3. Multivariate analysis of mortality in the incident (A) and prevalent (B) female and male chronic hemodialysis patients

|                  | (A)             | (B)             |
|------------------|-----------------|-----------------|
| P                | HR 95.0% CI for HR |
| Age              | <0.001 | 1.028 1.018 1.037 |
| Gender (female)  | 0.784 0.1037 0.802 1.340 |
| Dialysis vintage | 0.425 1.051 0.931 1.186 |
| BMI              | <0.001 | 0.943 0.920 0.967 |
| DM               | 0.852 0.979 0.781 1.227 |
| Vascular access (AVF) | <0.001 | 0.105 1.970 0.869 4.471 |
| AVG              | <0.001 | 3.132 2.200 4.459 |
| Untunneled catheter | <0.001 | 1.854 1.422 2.418 |
| Tunneled catheter | <0.001 | 1.051 0.543 2.035 |
| Various vascular access | 0.884 | 1.051 0.543 2.035 |
| Kt/V             | <0.001 | 0.210 0.120 0.368 |
| Blood pump rate  | 0.034 0.988 0.977 0.999 |
| Processed blood volume | 0.172 | 1.032 0.987 1.079 |
| IDWG/dry weight  | 0.067 0.000 0.000 1.887 |
| Hemoglobin       | <0.001 | 0.743 0.673 0.820 |
| Albumin          | <0.001 | 0.413 0.312 0.547 |
| Total calcium    | 0.007 1.343 1.084 1.665 |
| Phosphorus       | 0.950 1.004 0.895 1.126 |
| iPTH             | 0.778 1.000 1.000 1.001 |

BMI, body mass index; AVF, arteriovenous fistula; AVG, arteriovenous graft; IDWG, interdialytic weight gain; DM, diabetes mellitus; UPG, intact parathyroid hormone; HR, hazard ratio; CI, confidence interval.
might have provided a clue for observing the evolution in demographic, clinical and laboratory features of chronic hemodialysis patients over time. When analyzing survival probability, marginal values were used for some parameters at the expense of neglecting a continuum in their range. As an example, for analyzing the association of survival with hemoglobin levels, values of <9, 11–12 and >13 g/dL were used, while statistics for hemoglobin levels of 9–11 or 12–13 g/dL were skipped. The reason for this policy was to exclude the blunting effects of gray-zone values and focusing on the influence of extreme values on the survival.

Female patients were older in both incident and prevalent cases, reflecting the general trend of higher age in female chronic kidney disease patients [8]. Higher mean age in the incident group when compared with prevalent cases clearly shows that the dialysis population is getting older, as already has been described in other countries [9]. On the other hand, this finding may well be due to a selection bias, because prevalent patients are composed of the survivors, whereas elderly patients might have died previously.

Our data show that in both incident and prevalent patients, when compared with the reference values, higher than ideal BMI was associated with better survival in both genders. The association between BMI and prognosis is controversial; a reverse epidemiology may exist [10], and low body weight may be a disadvantage for survival [11]. A ‘U-shaped’ curve has also been reported in younger dialysis patients, which suggests that low or very high BMI is associated with elevated risk for death [12]. In the present analysis, the frequency of diabetes was higher in the incident (36.8%) when compared with the prevalent (27.7%) cases, possibly because of increasing number of diabetic patients in the general population over time [13], improved life expectancy in diabetic patients [14] and a progressive increase in the aging population, which is associated with a higher risk of type II diabetes [13].

Despite varying statistics among different counties, almost universally, fistula usage is more frequent among males [5, 15], a finding confirmed by this study as well. Difficulties in surgical technique in constructing AVF due to anatomic reasons [16] and more frequent fistula thrombosis due to higher levels of estrogen [17], and unwillingness of the surgeons because of concerns about higher failure rates, may play a role in the lower AVF usage in the females. Achievement of IDWG of <5.7% of dry weight is associated with improved survival [18–20]. Since there are major barriers such as nonadherence with dietary prescription, application of too short or ineffective dialysis or using high sodium-containing dialysates [20], this target cannot be achieved in many patients. In the present study, in the incident patients, IDWG/dry weight was significantly lower in incident cases when compared with prevalent cases, possibly due to better preserved residual renal function. This parameter was significantly lower in incident and prevalent female patients; the reason for this finding is obscure. In a cross-sectional multicenter comparative study, male sex was found to be an independent predictor for nonadherence to the fluid restriction [6], although this finding is controversial [21].

Considering laboratory parameters, controversy exists on fluid restriction [6], although this finding is controversial [21].

### Table 4. Three-year survival rates with regard to several parameters in the prevalent male and female patients

| Parameter | Reference | >Reference | P** |
|-----------|-----------|------------|-----|
| BMI       | P*        | <21 kg/m² (n) | 21–25 kg/m² (n) | >25 kg/m² (n) | P** |
| Female    | 0.210     | 71.9% (643)  | 74.4% (895)     | 79.3% (1673)  | 0.03 |
| Male      | <0.001    | 68.3% (814)  | 76.8% (1625)    | 81.2% (1729)  | 0.003 |
| IDWG/dry weight | <1.7% | 1.7–5.1%     | >5.1%           |           |
| Female    | 0.003     | 69.6% (304)  | 76.9% (2637)    | 82.0% (260)   | 0.1  |
| Male      | <0.001    | 61.6% (302)  | 77.2% (3433)    | 84.8% (374)   | 0.09 |
| Predialysis systolic BP | <100 mmHg | 120–140 mmHg | >200 mmHg |
| Female    | 0.755     | 79.5% (243)  | 77.4% (1560)    | *** (2)       | ***  |
| Male      | 0.036     | 74.2% (139)  | 78.6% (2281)    | *** (6)       | ***  |
| Kt/V      | <1.2      | 1.2–1.4      | >1.4            |           |
| Female    | <0.001    | 45.2% (108)  | 68.9% (665)     | 79.7% (2109)  | <0.001 |
| Male      | <0.001    | 59.3% (460)  | 77.6% (2033)    | 79.8% (1146)  | 0.6  |
| Hb        | <9 g/dL   | 11–12 g/dL   | >13 g/dL        |           |
| Female    | <0.001    | 61.4% (100)  | 80.6% (1332)    | 67.6% (132)   | 0.02 |
| Male      | <0.001    | 32.2% (87)   | 79.0% (1515)    | 86.1% (494)   | 0.002 |
| Phosphorus| <3.5 mg/dL| 3.5–5.5 mg/dL| >5.5 mg/dL      |           |
| Female    | <0.001    | 55.9% (292)  | 77.2% (2047)    | 83.1% (n: 625)| 0.09 |
| Male      | <0.001    | 53.5% (336)  | 77.5% (2377)    | 81.6% (1034)  | 0.02 |
| PTH       | <130 pg/mL| 130–585 pg/mL| >585 pg/mL      |           |
| Female    | <0.001    | 62.0% (355)  | 78.3% (1851)    | 81.7% (445)   | 0.3  |
| Male      | <0.001    | 61.9% (393)  | 78.4% (2301)    | 83.8% (643)   | 0.01 |
| Albumin   | <3.5 g/dL | 3.5–4 g/dL   | >4 g/dL         |           |
| Female    | <0.001    | 35.4% (193)  | 75.6% (1769)    | 84.3% (989)   | <0.001 |
| Male      | <0.001    | 25.1% (239)  | 73.1% (1764)    | 86.1% (1747)  | <0.001 |

BMI, body mass index; BP, blood pressure; Hb, hemoglobin; PTH, parathyroid hormone; IDWG, interdiaytic weight gain.
P*: statistics for comparing lower values than the reference.
P**: statistics for comparing higher values than the reference.

*": statistics unavailable because of insufficient number of patients or a follow-up <3 years.
In conclusion, although several parameters vary significantly, survival rates do not differ significantly in male and female hemodialysis patients. This finding may be due to mutual existence of several favorable and unfavorable confounding prognostic factors in both sexes, which may offset each other, hence, in the end, resulting in an overall nonsignificance. Importantly, this article raises also the question of a unique target for all patients in the various recommendations. Focusing on the correct parameters in each sex, and individualizing treatment protocols, may improve the ultimate outcome in both female and male hemodialysis patients.

Acknowledgements

This study was presented as a poster in Kidney Week 2013, Atlanta (Abstract No.: 2863). This study was supported by Fresenius Medical Care – Turkey. The authors thank Züleybede Arat, MD (Arat Research, Education, Consultancy Office), who performed the statistical analysis of this study.

Conflict of interest statement

F.K. works in Fresenius Medical Care–Turkey. The other authors declare that they have no conflict of interest.

References

1. Collins AJ, Foley RN, Chavers B et al. US Renal Data System 2013 Annual Data Report. Am J Kidney Dis 2014; 63 (1 Suppl): A7
2. Beck G, Biber BA, Ethier J et al. Sex-specific differences in hemodialysis prevalence and practices and the male-to-female mortality rate: the Dialysis Outcomes and Practice Patterns Study (DOPPS). PLoS Med 2014; 11: e1001750
3. Depner T, Dau girad a S, Greene T et al. Dialysis dose and the effect of gender and body size on outcome in the HEMO Study. Kidney Int 2004; 65: 1386–1394
4. Di Iorio BR, Stellato D, De Santo NG et al. Association of gender and age with erythropoietin resistance in hemodialysis patients: role of menstrual status. Blood Purif 2004; 22: 423–427
5. Pisoni RL, Young EW, Dykstra DM et al. Vascular access use in Europe and the United States: results from the DOPPS. Kidney Int 2002; 61: 305–316
6. Kugler C, Maeding I, Russell CL. Non-adherence in patients on chronic hemodialysis: an international comparison study. J Nephrol 2011; 24: 366–375
7. Marcelli D, Kirchgessner J, Amato C et al. EuClID (European Clinical Database): a database comparing different realities. J Nephrol 2001; 14 (Suppl 4): S94–S100
8. Süleymanlar G, Utas C, Arinsoy T et al. A population-based survey of Chronic Renal Disease In Turkey— the CREDIT study. Nephrol Dial Transplant 2011; 26: 1862–1871
9. Canaud B, Tong L, Tentori F et al. Clinical practices and outcomes in elderly hemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol 2011; 6: 1651–1662
10. Wolfe RA, Ashby VB, Dau girad a S et al. Body size, dose of hemodialysis, and mortality. Am J Kidney Dis 2000; 35: 80–88
11. Yen TH, Lin JL, Lin-Tan DT et al. Association between body mass and mortality in maintenance hemodialysis patients. Ther Apher Dial 2010; 14: 400–408
12. Hoogeveen EK, Halbesma N, Rothman KJ et al. Obesity and mortality risk among younger dialysis patients. Clin J Am Soc Nephrol 2012; 7: 280–288
13. Satman I, Omer B, Tutuncu Y et al. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol 2013; 28: 169–180
14. Brown A, Reynolds LR, Brummeir D. Intensive glycemic control and cardiovascular disease: an update. Nat Rev Cardiol 2010; 7: 369–375
15. Ethier J, Mendelsohn DC, Elder SJ et al. Vascular access use and outcomes: an international perspective from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2008; 23: 3219–3226
16. Vernaglione L, Mele G, Cristofano C et al. Comorbidity conditions and gender impact the primary survival of dialysis patients. Clin J Am Soc Nephrol 2005; 18: 276–281
17. Middeldorp S. Thrombosis in women: what are the knowledge gaps in 2013? J Thromb Haemost 2013; 11 (Suppl 1): 180–191
18. Leggat JE Jr, Orzol SM, Hulbert-Shearon TE et al. Noncompliance in hemodialysis: predictors and survival analysis. Am J Kidney Dis 1998; 32: 139–145
19. Port FK, Pisoni RL, Bragg-Gresham JL et al. DOPPS estimates of patient life years attributable to modifiable hemodialysis practices in the United States. Blood Purif 2004; 22: 175–180
20. Agarwal R, Weir MR. Dry-weight: a concept revisited in an effort to avoid medication-directed approaches for blood pressure control in hemodialysis patients. Clin J Am Soc Nephrol 2010; 5: 1255–1260
21. Lopez-Gomez JM, Villaverde M, Jofre R et al. Interdialytic weight gain as a marker of blood pressure, nutrition, and survival in hemodialysis patients. *Kidney Int Suppl* 2005; (93): S63–S68

22. Daugirdas JT. Dialysis dosing for chronic hemodialysis: beyond Kt/V. *Semin Dial* 2014; 27: 98–107

23. Vaiciuniene R, Kuzminskis V, Ziginskiene E et al. Adherence to treatment and hospitalization risk in hemodialysis patients. *J Nephrol* 2012; 25: 672–678

24. Kimmel PL, Peterson RA, Weihs KL et al. Behavioral compliance with dialysis prescription in hemodialysis patients. *J Am Soc Nephrol* 1995; 5: 1826–1834

25. Floege J, Kim J, Ireland E et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. *Nephrol Dial Transplant* 2011; 26: 1948–1955

26. Ho LT, Sprague SM. Women and CKD-mineral and bone disorder. *Adv Chronic Kidney Dis* 2013; 20: 423–426

27. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. *Kidney Int* 2006; 70: 771–780

28. Cheng SP, Yang TL, Lee JJ et al. Gender differences among patients with secondary hyperparathyroidism undergoing parathyroidectomy. *J Surg Res* 2011; 168: 82–87

29. Gupta A, Kallenbach LR, Zasuwa G et al. Race is a major determinant of secondary hyperparathyroidism in uremic patients. *J Am Soc Nephrol* 2000; 11: 330–334

30. Webb L, Gilg J, Wilkie M. Chapter 8 Haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2010: national and centre-specific analyses. *Nephron Clin Pract* 2012; 120 (Suppl 1): c145–c174

31. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. *Am J Kidney Dis* 2001; 37 (1 Suppl 1): S182–S238